Observations placeholder
Midodrine Hydrochloride
Identifier
019532
Type of Spiritual Experience
Background
A description of the experience
Midodrine (brand names Amatine, ProAmatine, Gutron) is a vasopressor/antihypotensive agent. Midodrine was approved in the United States by the Food and Drug Administration (FDA) in 1996 for the treatment of dysautonomia and orthostatic hypotension. In August 2010, the FDA proposed withdrawing this approval because the manufacturer, Shire plc, has failed to complete required studies after the medicine reached the market.
In September 2010, the FDA reversed its decision to remove Midodrine from the market and has allowed it to remain available to patients while Shire plc collects further data regarding the efficacy and safety of the drug. Shire plc announced on September 27, 2011 that it was continuing the process to work with the FDA towards a final approval of the drug
Side effects
Headache; feeling of pressure/fullness in the head, vasodilation/flushing face, confusion/thinking abnormality, dry mouth; nervousness/anxiety and rash.
On Dec, 22, 2015: 1,056 people reported to have side effects when taking Midodrine hydrochloride. Among them, 16 people (1.52%) have Hallucination.
Time on Midodrine hydrochloride when people have Hallucination :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Hallucination | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
On Dec, 17, 2015: 1,056 people reported to have side effects when taking Midodrine hydrochloride. Among them, 34 people (3.22%) have Death.
Time on Midodrine hydrochloride when people have Death :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Death | 12.50% | 87.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Midodrine hydrochloride :
Female | Male | |
Death | 39.47% | 60.53% |
Age of people who have Death when taking Midodrine hydrochloride :
0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
Death | 0.00% | 0.00% | 0.00% | 0.00% | 6.06% | 0.00% | 12.12% | 81.82% |